Sequential gene targeting to make chimeric tumor models with de novo chromosomal abnormalities

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1588-1597

  Chambers, Jennifer S ^a,b   Tanaka, Tomoyuki ^b,d   Brend, Tim ^a,b   Ali, Hanif ^b,e   Geisler, Nicola J ^b,f   Khazin, Leah ^b   Cigudosa, Juan C ^c   Dear, T Neil ^b,g   MacLennan, Kenneth ^b   Rabbitts, Terence H ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c Structural Biology and Biocomputing Programme   (Spain)

^d RandD and Manufacturing Group   (Japan)

^e Babraham Research Campus ^*  (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; EMBRYONIC STEM CELL; ENL GENE; EXPERIMENTAL MODEL; GENE FREQUENCY; GENE FUSION; GENE TARGETING; GENOME ANALYSIS; HOMOLOGOUS RECOMBINATION; LEUKOCYTOSIS; MLL GENE; MOUSE; MUTATIONAL ANALYSIS; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR MODEL;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CHROMOSOME ABERRATIONS; EMBRYONIC STEM CELLS; GENE TARGETING; HUMANS; LEUKOCYTOSIS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; ONCOGENE PROTEINS, FUSION; STEM CELLS; TRANSLOCATION, GENETIC;

EID: 84896517071     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1783     Document Type: Article

References (20)

1. Rabbitts TH., Commonality but diversity in cancer gene fusions. Cell 2009;137:391-5.
2. Schichman SA, Canaani E, Croce CM. Self-fusion of the ALL1 gene A new genetic mechanism for acute leukemia. JAMA 1995;273:571-6.
3. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
4. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994;372:143-9.
5. Smith AJ, De Sousa MA, Kwabi-Addo B, Heppell-Parton A, Impey H, Rabbitts P.Asite-directed chromosomal translocation inducedinembryonic stem cells by Cre-loxP recombination. Nat Genet 1995;9:376-84.
6. van Deursen J, Fornerod M, Van Rees B, Grosveld G. Cre-mediated site-specific translocation between nonhomologous mouse chromosomes. Proc Natl Acad Sci U S A 1995;92:7376-80.
7. Collins EC, Pannell R, Simpson EM, Forster A, Rabbitts TH. Interchromosomal recombination of Mll and Af9 genes mediated by creloxP in mouse development. EMBO Rep 2000;1:127-32.
8. Buchholz F, Refaeli Y, Trumpp A, Bishop JM. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep 2000;1:133-9.
9. Forster A, Pannell R, Drynan LF, McCormack M, Collins EC, Daser A, et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 2003;3:449-58.
10. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, et al. An Mll-Af9 fusion genemade by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996;85:853-61.
11. Forster A, Pannell R, Drynan LF, Codrington R, Daser A, Metzler M, et al. The invertor knock-in conditional chromosomal translocation mimic. Nat Methods 2005;2:27-30.
12. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH, et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 78:45-58.
13. Tucker KL, WangY, Dausman J, Jaenisch R.Atransgenic mouse strain expressing four drug-selectable marker genes. Nucleic Acids Res 1997;25:3745-6.
14. Drynan LF, Pannell R, Forster A, Chan NM, Cano F, Daser A, et al. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis. EMBO J 2005;24: 3136-46.
15. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997;278:1059-65.
16. Di Martino JF, Cleary ML. MLL rearrangements in haematological maligancies: lessons from clinical and biological studies. Br J Haematol 1999;106:614-26.
17. Zhou Y, RideoutWMIII, Zi T, Bressel A, Reddypalli S, Rancourt R, et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family-And KRAS-dependent lung adenocarcinomas. Nat Biotechnol 2010;28:71-8.
18. Szymczak AL, Vignali DA. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 2005; 5:627-38.
19. Ono R, Nakajima H, Ozaki K, Kumagai H, Kawashima T, Taki T, et al. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest 2005;115: 919-29.
20. Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, et al. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia 2008;22:66-77.